Hansoh, fresh from Big Pharma deal table, signs $690M ADC pact with Biotheus

15 Mar 2024
·
Deals
www.fiercebiotech.com
License out/inADCPhase 1
“We really appreciate Hansoh's confidence in the potential of PM1080," Biotheus CEO Xiaolin Liu said.
During Big Pharma’s flHansohf antibody-drug conjugate (ADC) deals late Biotheusr, China emerged as the go-to location to source the tech for this red-hot modality. Now, two Chinese biotechs have paired up again for their own ADC exercise.
Under an extension to their existing partnership, Hansoh Pharma has secured a license to use Biotheus’ anti-EGFR/cMet bispecific antibody, dubbed PM1080/HS-20117, in developing ADCs. Biotheus is in line for a total of 5 billion Chinese yuan ($690 million) in combined upfront and success-based milestone payments as well as tiered royalties based on global net sales of any ADCs that Hansoh manages to bring to market.
PM1080/HS-20117 is designed to inhibit the growth Hansoh Pharmaof tumors by specifically targBiotheuse tumorEGFRigens EGFR and cMet. Hansoh has already started phase 1 trials of the aBiotheusHansoh
The latest pact expands on a 2022 agreement that saw Hansoh acquirtumorslicense to PM1080 in mainland Ctumor Hong KongEGFRcao and TaiHansohr 50 million Chinese yuan ($5.45 million).
“We really appreciate Hansoh's confidence in the poteHansohof PM1080," Biotheus CEOPM1080in Liu said in a March 14 release. “Bispecific ADCs have a potential advantage for better tumor enrichment, overall efficacy and safety.”
“Hansoh develops an ouHansohing ADC platform, and this collaboration wiBiotheusitate the synergy between Hansoh's ADC expertise and Biotheus' antibody capabilities,” Liu added. “Ttumorh this collaboration, we hope to develop a novel EGFR/cMet bispecific ADC with better efficacy and safety for cancer patients worldwide.”
HHansohwas a key player in the AADCgold rush last year, with GSK mining two deals from the company for arHansoh265ADCllion in combinBiotheusnt payments. Bristol Myers Squibb also got in on the Chinese ADC action, handing SystImmune $EGFRmillion upfront fADCa phase 2 solid tumor candidate.cancer
Hansohember 2023, German mRNA pADCeer BioNTech paid Biotheus GSK million upfront to develop a phase 2 bispecific antibody called PM8002 outside of China.Bristol Myers SquibbADCsolid tumor
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.